Yingjie Zhang
Gender:Male
Education Level:Postgraduate (Doctoral)
Alma Mater:山东大学
Scientific Research
Paper Publications
-
. Dual targeting PPARα and NPC1L1 metabolic vulnerabilities blocks tumorigenesis. Cancer letters, 612, 2025.
-
. HDAC11 Inhibition as a Potential Therapeutic Strategy for AML: Target Identification, Lead Discovery, Antitumor Potency, and Mechanism Investigation. Journal of Medicinal Chemistry, 2025.
-
. Discovery of epigenetic modulators targeting HDACs and EZH2 simultaneously for the treatment of hematological malignancies. Bioorganic Chemistry, 153, 2025.
-
. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer. Journal of Medicianal Chemistry, 66, 2024.
-
. Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity. J. Med. Chem. , 66, 10080, 2023.